RBC Keeps Outperform on Axsome, Cites AXS-05 Upside from Alzheimer’s Agitation Opportunity
RBC Capital reiterated an Outperform rating on Axsome Therapeutics (AXSM) with a $219 price target, placing emphasis on the commercial opportunity for AXS-05 in Agitation in Alzheimer’s Disease (ADA). The firm compared prescribing patterns for a competitor drug to assess market potential and flagged AXS-05’s safety and efficacy as competitive advan…